
    
      The total study participant time is expected to be approximately 14 weeks from time of
      screening to completion of study. Subjects will be instructed on the use of ROSF and receive
      the first dose of ROSF under supervision of the investigator during Visit 1.Subjects will
      then continue on ROSF 50mg twice daily for 12 weeks.
    
  